DR info

Clinical trials : 42 / Drugs : 71 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 112

Drugs and their primary sponsors and trial info

00305800
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001948-19-IT   Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
1643368-58-4
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
ADX-102 Topical Dermal Cream (reproxalap)
   Aldeyra Therapeutics, Inc.
      2018   Phase 3   NCT03445650   United States;
Active topical NS2 dermatologic cream
   Aldeyra Therapeutics, Inc.
      2015   Phase 2   NCT02402309   United States;
Adalimumab
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 2   NCT02113904   France;
Apply VEREGEN ® on a randomized area and the moisturizing cream of the other side
   Centre Hospitalier Universitaire de Nice
      2010   Phase 3   NCT01222000   France;
Atorvastatin
   Kubo Akiharu
      2013   Phase 2   JPRN-jRCTs031180409   Japan;
BMS-931699
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
BMS-986142
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
BMS986142
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
BPR277
   Novartis Pharma Services AG
      2013   -   EUCTR2011-000917-38-NL   France;Germany;Netherlands;United States;
      2011   -   EUCTR2011-000917-38-DE   France;Germany;Netherlands;United States;
BPR277 ointment (controlled application)
   Novartis Pharmaceuticals
      2011   Phase 1   NCT01428297   France;Germany;Netherlands;United States;
BTK Inhibitor
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States;
CNT-02
   Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
      2016   -   NCT02830763   Italy;Japan;
Cholesterol
   Kubo Akiharu
      2013   Phase 2   JPRN-jRCTs031180409   Japan;
Dupilumab Injection
   National Medical Research Center for Children's Health, Russian Federation
      2021   Phase 4   NCT04996485   Russian Federation;
Dupilumab Prefilled Syringe
   University Hospital, Toulouse
      2020   Phase 2/Phase 3   NCT04244006   France;
Dupixent
   CHU de Toulouse
      2019   Phase 2   EUCTR2019-001220-35-FR   France;
Epithelial sheet generated from transduced autologous keratinocytes using pCCL-INVO-SP
   GOSH/ICH Joint Research & Development Office
      2013   Phase 1   EUCTR2011-003212-22-GB   United Kingdom;
Fibrate treatment
   Maastricht University Medical Center
      2011   Phase 4   NCT01527318   Netherlands;
Glucose
   University Hospital, Toulouse
      2015   -   NCT02383316   France;
Hematopoetic Stem Cell Transplantation
   University of Pittsburgh
      2012   -   NCT03333200   United States;
Humira
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2013   -   EUCTR2013-002205-54-FR   France;
Isotretinoin
   Timber Pharmceuticals LLC
      2019   Phase 2   NCT04154293   Australia;United States;
KB105
   Krystal Biotech, Inc.
      2019   Phase 1/Phase 2   NCT04047732   United States;
L04AB04
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2013   -   EUCTR2013-002205-54-FR   France;
Lipoxygenase inhibitor
   UMC St Radboud
      2009   Phase 3   EUCTR2009-015895-87-NL   Netherlands;
Lovastatin
   Northwestern University
      2011   Phase 2   NCT01110642   United States;
Monolaurin cream
   Cellegy Pharmaceuticals
      1996   Phase 3   NCT00004690   -
None
Orencia
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001948-19-IT   Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001948-19-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
      2016   Phase 3   EUCTR2016-001948-19-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
      2016   Phase 3   EUCTR2016-001948-19-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden;
Oxiconazole
   Kubo Akiharu
      2013   Phase 2   JPRN-jRCTs031180409   Japan;
PAT-001,
   Patagonia Pharmaceuticals, LLC
      2017   Phase 2   NCT02864082   United States;
Pimecrolimus Cream
   Children's Hospital of Philadelphia
      2005   Phase 1/Phase 2   NCT00208026   United States;
RVG 18388
SAR231893
   CHU de Toulouse
      2019   Phase 2   EUCTR2019-001220-35-FR   France;
SXR1096
   Sixera Pharma
      2022   Phase 1;Phase 2   EUCTR2021-003210-39-AT   Austria;Finland;
      2021   Phase 1;Phase 2   EUCTR2021-003210-39-FI   Finland;
Secukinumab
   Northwestern University
      2016   Phase 2   NCT03041038   United States;
Secukinumab Injection
   National Medical Research Center for Children's Health, Russian Federation
      2021   Phase 4   NCT04996485   Russian Federation;
Simvastatin
   Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
      2020   Phase 0   ChiCTR2000037278   China;
Ustekinumab Injection
   National Medical Research Center for Children's Health, Russian Federation
      2021   Phase 4   NCT04996485   Russian Federation;
VEREGEN(R)
   Nice University Hospital
      2009   -   EUCTR2009-013656-77-FR   France;
Vehicle
   Patagonia Pharmaceuticals, LLC
      2017   Phase 2   NCT02864082   United States;
Vehicle of ADX-102 Topical Dermal Cream
   Aldeyra Therapeutics, Inc.
      2018   Phase 3   NCT03445650   United States;
Zyflo CR
   UMC St Radboud
      2009   Phase 3   EUCTR2009-015895-87-NL   Netherlands;